Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP624372.RA9lra33_Z2KvzWUh9yT_4wDXagwOJn2I5ukqF-fCeLQo130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP624372.RA9lra33_Z2KvzWUh9yT_4wDXagwOJn2I5ukqF-fCeLQo130_assertion type Assertion NP624372.RA9lra33_Z2KvzWUh9yT_4wDXagwOJn2I5ukqF-fCeLQo130_head.
- NP624372.RA9lra33_Z2KvzWUh9yT_4wDXagwOJn2I5ukqF-fCeLQo130_assertion description "[The higher signature score in metastatic compared to primary lesions, and the potential link to PI3K activation and EMT, support further studies of ECARS in relation to response to PI3K and EMT inhibitors in clinical trials of metastatic endometrial carcinoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP624372.RA9lra33_Z2KvzWUh9yT_4wDXagwOJn2I5ukqF-fCeLQo130_provenance.
- NP624372.RA9lra33_Z2KvzWUh9yT_4wDXagwOJn2I5ukqF-fCeLQo130_assertion evidence source_evidence_literature NP624372.RA9lra33_Z2KvzWUh9yT_4wDXagwOJn2I5ukqF-fCeLQo130_provenance.
- NP624372.RA9lra33_Z2KvzWUh9yT_4wDXagwOJn2I5ukqF-fCeLQo130_assertion SIO_000772 24995579 NP624372.RA9lra33_Z2KvzWUh9yT_4wDXagwOJn2I5ukqF-fCeLQo130_provenance.
- NP624372.RA9lra33_Z2KvzWUh9yT_4wDXagwOJn2I5ukqF-fCeLQo130_assertion wasDerivedFrom befree-20150227 NP624372.RA9lra33_Z2KvzWUh9yT_4wDXagwOJn2I5ukqF-fCeLQo130_provenance.
- NP624372.RA9lra33_Z2KvzWUh9yT_4wDXagwOJn2I5ukqF-fCeLQo130_assertion wasGeneratedBy ECO_0000203 NP624372.RA9lra33_Z2KvzWUh9yT_4wDXagwOJn2I5ukqF-fCeLQo130_provenance.